Back
ESC Premium Access

Type of P2Y12 inhibitor at the acute stage and one-year mortality in acute myocardial infarction. The FAST-MI programme

Session: Oral P2Y12 inhibitors in acute coronary syndromes: are they all equal?
Topic: Pharmacotherapy
Speaker: Professor N. Danchin (Paris, FR)
Event: ESC Congress 2018

Congress Presentation

About the speaker

Professor Nicolas Danchin

Saint Joseph Hospital, Paris (France)
18 presentations
0 follower

5 more presentations in this session

A head-to-head comparison of uniform prasugrel treatment vs. clopidogrel treatment for confirmed responders in acute coronary syndrome patients: results from the randomized TROPICAL-ACS trial

Speaker: Doctor R. Hein (Munich, DE)

Access
Abstract
Slides
Video
Thumbnail

Prasugrel vs Ticagrelor in patients with acute coronary syndrome and diabetes: a propensity match substudy of RENAMI

Speaker: Doctor M. Bertaina (Turin, IT)

Access
Abstract
Slides
Video
Thumbnail

Next generation P2Y12 inhibitors improve survival in ACS: An analysis from the British Cardiovascular Intervention Society database.

Speaker: Doctor H. Contractor (Manchester, GB)

Access
Abstract
Slides
Video
Thumbnail

Prognostic impact of the new P2Y12 (ticagrelor and prasugrel) versus clopidogrel in acute coronary syndrome patients in relation to renal function

Speaker: Mrs M. Castineira Busto (Vigo, ES)

Access
Abstract
Slides
Video
Thumbnail

The OPTIDUAL trial: long term follow-up

Speaker: Professor G. Helft (Paris, FR)

Access
Abstract
Video
Thumbnail

Access the full session

Oral P2Y12 inhibitors in acute coronary syndromes: are they all equal?

Speakers: Professor N. Danchin, Doctor R. Hein, Doctor M. Bertaina, Doctor H. Contractor, Mrs M. Castineira Busto...
Access
Thumbnail

About the event

Image

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb